# Juan W. Valle

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/juan-w-valle/

## Facts

| Field | Value |
| --- | --- |
| Citations | 52,073 |
| Field | Cholangiocarcinoma and Gallbladder Cancer Studies |
| h-index | 86 |
| i10-index | 316 |
| Last Known Institution | University of Manchester |
| OpenAlex ID | https://openalex.org/A5077826150 |
| ORCID iD | https://orcid.org/0000-0002-1999-0863 |
| Works | 780 |

## Researcher papers

- [Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors](https://scholariq.org/papers/sunitinib-malate-for-the-treatment-of-pancreatic-neuroendocrine-tumors/)
- [Cholangiocarcinoma 2020: the next horizon in mechanisms and management](https://scholariq.org/papers/cholangiocarcinoma-2020-the-next-horizon-in-mechanisms-and-management/)
- [Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/everolimus-for-the-treatment-of-advanced-non-functional-neuroendocrine-tumours/)
- [Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-in-combination-with-gemcitabine-and-cisplatin-compared-with/)
- [Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)](https://scholariq.org/papers/guidelines-for-the-management-of-gastroenteropancreatic-neuroendocrine-including/)
- [Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial](https://scholariq.org/papers/second-line-folfox-chemotherapy-versus-active-symptom-control-for-advanced/)
- [Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/biliary-tract-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment/)
- [ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging](https://scholariq.org/papers/enets-consensus-guidelines-for-the-standards-of-care-in-neuroendocrine-tumors/)
- [Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry](https://scholariq.org/papers/cholangiocarcinoma-landscape-in-europe-diagnostic-prognostic-and-therapeutic/)
- [Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome](https://scholariq.org/papers/telotristat-ethyl-a-tryptophan-hydroxylase-inhibitor-for-the-treatment-of/)

## Researcher topics

- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Gallbladder and Bile Duct Disorders](https://scholariq.org/topics/gallbladder-and-bile-duct-disorders/)

## Researcher university

- [University of Manchester](https://scholariq.org/institutions/university-of-manchester/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.